Business
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY o
About this update from Pyxis Oncology, Inc.
[{"type":"image","alt":"Pyxis Oncology","displaySize":"","headline":null,"caption":"Pyxis Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":203,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/c663fbbdcef74ec76700a29d86aa098c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IX0t534d6HFsYbdc2gj8WA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c663fbbdcef74ec76700a29d86aa098c","width":203,"height":105}},"lazy":false},{"type":"text","content":"BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences.","length":428,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05 p.m. ET","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Jefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET","length":90,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":196,"olType":false},{"type":"text","content":"A live webcast and replay of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.","length":189,"tagName":"p"},{"type":"text","content":"About Pyxis Oncology, Inc.Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1...